Low concentrations of an nitric oxide-donor combined with a liposoluble antioxidant compound enhance protection against reperfusion injury in isolated rat hearts by Rastaldo, R et al.
INTRODUCTION
Although required to allow myocardium to recover after an
infarction, post-ischemic reperfusion produces several negative
effects, e.g. myocardial stunning and increase in infarct size,
which result in the so called reperfusion injury (1-3). Both a
burst of reactive oxygen species (ROS) and an altered release of
nitric oxide (NO) during reperfusion are believed to contribute to
reperfusion injury (4-6). Thus, antioxidant therapy has been
proposed as a possible intervention to limit myocardial
ischemia/reperfusion (I/R) injury. However, clinical studies have
been disappointing, since the various antioxidants employed in
reperfusion produced limited or even negative effects (7-10).
NO-donors have also been proposed as possible cardioprotective
agents (7, 8), with conflicting results as well (11, 12).
Besides pharmacokinetics issues, the I/R scenario and its
prevention are in fact more intricate than they appeared at a first
glance. Paradoxically protection may in fact be achieved by
ischemic pre- (IP) and post-conditioning (PostC), i.e. brief
coronary occlusions performed either before or immediately after
an infarcting ischemia, respectively. Even more paradoxically,
ROS production during early reperfusion represents an important
step toward the limitation of infarct size in both settings (13-16).
In fact, protection by IP and PostC was suppressed by antioxidant
administration right at the beginning of reperfusion (13-19).
Thus, a better knowledge of the signaling cascades leading to
protection suggests that a blanket reduction in ROS levels with a
broad-spectrum antioxidant is highly unlikely to selectively target
detrimental effects of oxidative stress.
In these protective cascades opening of mitochondrial ATP-
sensitive K+ (mKATP) channels is considered to be a key point
towards protection (4, 13, 15, 19-21). In fact, activation of the
NO-cGMP-protein kinase G (PKG) pathway may result in
opening of mKATP channels and subsequent mitochondrial ROS
production, which in turn activates protein kinase C (PKC) and
induces protection (4, 5, 12, 13, 15, 22).
Yet, during reperfusion the role of ROS in the protective
pathway is more subtle and delicate. For instance, before
ischemia exogenous ROS may trigger preconditioning-like
protection (23), while if given during the early reperfusion they
are unable to trigger a postconditioning-like protection (15). It is
likely that protective ROS in reperfusion are produced in a
regulated and spatially confined manner (15, 22).
In addition, ROS may interact with NO leading to its
inactivation and formation of nitrogen reactive species with
either beneficial or detrimental effect (4, 22). Antioxidants may
prevent NO degradation, further increasing its bioavailability,
and therefore combined administration of antioxidants and NO-
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NO-donor and an antioxidant compound against ischemia/reperfusion were studied. The compounds were tested
separately, as a mixture and as a new hybrid molecule containing both leads. Isolated rat hearts underwent 30 min global
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reperfusion. Hybrid was also tested in the presence of mitochondrial K+ ATP-sensitive (mKATP) channel blockade by
5-HD (100 µM). Reduction of infarct size and recovery of left ventricular developed pressure during reperfusion were
evaluated. When given at 1 µM concentration, hybrid significantly improved all indices of protection; its beneficial
effects were abolished by mKATP channel blockade. At the same concentration, mixture and NO-donor alone improved
recovery of left ventricular developed pressure but did not reduce infarct size; antioxidant was ineffective. When given
at 10 µM concentration, antioxidant and mixture improved all parameters of protection; NO-donor and hybrid were
ineffective. Our data suggest that different signaling cascades could be elicited by low and high concentrations of
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donors has been put forward as a therapeutic strategy to prevent
I/R-mediated myocardial injury. In this regard, in isolated rat
hearts combined administration of a NO-donor and Tempol, a
superoxide-dismutase mimetic, has indeed shown a protective
effect, but if given before ischemia (24), i.e. when it has little
clinical application (8, 22).
Taken together, the above reported data suggest that NO and
ROS interaction during reperfusion may affect the outcome of
I/R. We thus hypothesized that administration during early
reperfusion of a novel hybrid compound with NO-donor (6) and
cell permeable antioxidant leads may provide a better
myocardial protection than either single lead given separately or
as a mixture. We have evaluated two different concentrations of
these compounds, which yield different levels of cell
permeation, NO bioavailability and/or more complete ROS
removal. Finally, we tested whether hybrid effects on I/R injury
may be mediated by activation of mKATP channels.
MATERIALS AND METHODS
Animals
Six months old male Wistar rats (Harlan, S. Pietro al
Natisone, Italy) were used for this study. The present
investigation conforms with the Italian ethical guidelines (DL.
116, 27 Jan, 1996) and with the Guide for Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication N. 85-23, revised 1996). The purposes
and the protocols of our studies have been approved by the
Ministero della Salute (Ministry of Health), Rome, Italy and by
the local ethical committee of the University of Turin.
Chemicals
All chemicals for the buffer solution, dimethyl sulfoxide
(DMSO), 5-hydroxydecanoic acid (5-HD) and the antioxidant
compound (AOX) 2,2,5,7,8-pentamethylchroman-6-ol, the
phenol substructure present in vitamin E, were purchased from
Sigma (USA) (Fig.1); the reagents necessary to assess
myocardial infarction were purchased from Merck (USA). NO-
donor (NOD) compound 4-[(dimethylamino)methyl]furoxan-3-
carboxyamide, and the hybrid (HYB) 4-((N-((6-hydroxy-
2,5,7,8-tetramethylchroman-2-yl)methyl)-N-methylamino)
methyl)furoxan-3-carboxamide (Fig. 1) were synthesized and
characterized as nitric oxide donors in the laboratories of the
Department of Drugs Science and Technology, University of
Turin (6). In particular, the release of NO by NOD and HYB was
shown by the impairment of the relaxation of denuded rat aortic
strip in the presence of a guanylyl cyclase inhibitor (6).
Isolated heart preparation
Ten minutes after intramuscular injection of heparin (200
UPS units), the animals were anaesthetised with urethane (1 g/kg)
given intraperitoneally. The heart was rapidly excised and placed
in ice-cold Krebs-Henseleit perfusion buffer. Aorta was then
attached to the cannula of the perfusion apparatus, and the heart
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Fig. 1. Structures of the NO-
donor/antioxidant hybrid (HYB)
4-((N-((6-hydroxy-2,5,7,8-
t e t r a m e t h y l c h r o m a n - 2 -
yl)methyl)-N-methylamino)
methyl)furoxan-3-carboxamide,
the parent antioxidant (AOX)
2,2,5,7,8-pentamethylchroman-
6-ol, and the NO-donor (NOD)
4-[(dimethylamino)methyl]
furoxan-3-carboxyamide.
Fig. 2. Time-lines and protocols
for the experimental groups.
was perfused at constant flow with a Krebs-Henseleit solution at
37°C containing NaCl (127 mM), NaHCO3 (17.7 mM), MgCl2
(1.26 mM), KCl (5.1 mM), CaCl2 (1.5 mM) and glucose (11
mM). The perfusion buffer was saturated with a 95% O2 and 5%
CO2 gas mixture as previously described (13, 15).
The constant flow was adjusted with a perfusion pump
(Watson-Marlow 505DU, Falmouth, Cornwall, UK) to achieve a
perfusion pressure of 80 mmHg during the stabilization. The
mean flow to reach this value was 9±1 ml/min/g wet weight.
A small hole in the left ventricular wall allowed the drainage
of the thebesian flow. To prevent possible changes in myocardial
metabolism in response to changes in heart rate, the hearts were
paced at 280 bpm by a Grass S11 stimulator (Grass Instruments,
Quincy, Mass, USA).
Experimental protocol
After 20 minutes of stabilization, all hearts underwent 30
minutes of global ischemia at 37°C, obtained by arresting
perfusion pump. Ischemia was followed by 2 hours of
reperfusion. Pacing was stopped at the beginning of the
ischemia and restarted after the third minute of reperfusion
(13,15). Hearts were randomly assigned to one of the following
groups (Fig. 2). Control Group 1 (n=7): hearts underwent
ischemia and reperfusion only, without pharmacological
interventions
The hearts of groups 2-9 were treated as follows: Group 2
(n=7): 1 µM NOD; Group 3 (n=6): 1 µM AOX; Group 4 (n=7):
1 µM AOX + 1 µM NOD (1 µM MIX); Group 5 (n=9): 1 µM
HYB; Group 6 (n=7): 10 µM NOD; Group 7 (n=8): 10 µM
AOX; Group 8 (n=9): 10 µM AOX +10 µM NOD (10 µM MIX);
Group 9 (n=7): 10 µM HYB.
Since the extent of the protective effects brought about by
ischemic postconditioning suggests that a great part of I/R injury
occurs during reperfusion (8, 13), treatments were started at the end
of ischemia to mimic the PostC and lasted 20 minutes to include
the entire period during which most of the injury takes place (8).
The two concentrations (1 and 10 µM) were chosen from the range
in which the HYB showed both the NO-donating and antioxidant
activities according to previous characterization (6).
Assessment of mKATP channel blockade
Since NO may lead to ROS production via mKATP channel
activation (21), two groups of hearts received the novel HYB at
the concentration of 1 µM (Group 10, n=5) or 10 µM (Group 11,
n=5) during blockade of mKATP channels with 5-HD at the
concentration of 100 µM, which "per se" does not alter the
response to ischemia/reperfusion (13).
Due to their liposolubility, HYB, and antioxidant were
dissolved in DMSO. In preliminary experiments DMSO,
administered alone at 0.1% concentration in Krebs-Henseleit
solution, did not exert any effect on myocardial I/R injury (data
not shown). This is consistent with what observed in previous
investigations (13, 14).
Cardiac function assessment
Left ventricular pressure was measured with the probe
(Monitoring kit mk5-02 DTNVF, Abbott, Milan, Italy) of a
pressure transducer (mod.: CL-810231, Gould inc., Instruments
division, Cleveland Ohio, USA) connected via a catheter to a
latex balloon placed in the left ventricle through the mitral valve.
The balloon was filled with a sufficient volume of distilled water
to achieve a left ventricular end diastolic pressure of 4-8 mmHg.
No further changes of ventricular volume were made during the
experiment.
Coronary perfusion pressure was measured with the probe of
another pressure transducer connected to the perfusion line. Left
ventricular pressure and coronary perfusion pressure were
continuously monitored and recorded by a data acquisition
system (Lab-View software, National Instrument Corporation,
Austin, Texas, USA).
Hemodynamic variables were analysed using Chart Software
(AD Instruments, Basile, Milan, Italy). *(LVDP) is expressed as
percent recovery with respect to the basal values before ischemia.
Infarct size measurement
At the end of the experiments all hearts were rapidly removed
from the perfusion apparatus. After isolation, the left ventricle
was cut in 1 mm thick slices. After 20 minutes incubation in 0.1%
solution of nitro-blue tetrazolium in phosphate buffer, stained
viable tissue was separated from unstained necrotic tissue and
then weighed by an independent observer (13, 15). Infarct size is
expressed as percentage of the left ventricular mass. Since global
ischemia was performed, the total mass of the left ventricle mass
corresponded to the risk area.
Statistical analysis
Data are expressed as means±SE. One-way ANOVA with
post hoc Tukey test were used to assess the statistical
significance of the changes of the studied variables.
RESULTS
1. Infarct size
In comparison with the control Group (54±3%), infarct size
was significantly reduced by 1 µM of HYB to 20±6% of the left
ventricle (p<0.01). No significant reduction was observed in
response to NOD, MIX or AOX (37±7%, 30±6%, and 48±6% of
the left ventricle, respectively; p=NS) (Fig.3, top panel).
2. Cardiac function assessment
A clear pulsatile activity (LVDP>15 mmHg) reappeared in 4
out of 7 hearts of the control group, in 6 out of 7 in NOD Group,
in 4 out of 6 in AOX Group, in 7 out of 7 in MIX Group and in
8 out of 9 in HYB Group.
Bottom panel of Fig. 3 shows the recovery of LVDP after 2
hrs of reperfusion. In comparison with controls (23±7%),
recovery of contractile function was significantly improved after
treatment with NOD (54±7%; p<0.05), MIX (61±6%; p<0.05) or
HYB (50±8%; p<0.05), but not after AOX (28±11%).
1. Infarct size
In comparison with controls (54±3%), infarct size was
significantly reduced by AOX to 23±3% (p<0.01) and by MIX
to 25±8% (p<0.05), but not by HYB or NOD (42±9% and
39±7% of left ventricle, respectively) (Fig. 4, top panel)
2. Cardiac function assessment
A clear pulsatile activity (LVDP>15 mmHg) reappeared in 5
out of 7 hearts after both HYB and NOD, in 9 out of 9 after MIX
and in 7 out of 8 after AOX. Bottom panel of Fig. 4 shows the
recovery of LVDP after 2 hrs of reperfusion. In comparison with
controls (23±7%) a significant recovery was observed after AOX
(50±4%; p<0.05) or MIX (49±4%; p<0.05), but not after the
other treatments.
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Fig. 3. Infarct size and recovery of left ventricular developed
pressure (LVDP) when drugs were administered at 1 µM
concentration. Top panel: Infarct size, measured as a percent of left
ventricular mass (% LV). Bottom panel: LVDP at the end of
reperfusion, expressed as percent of basal values before ischemia
(% BC). *p<0.05; **p < 0.01 vs. controls.
Fig. 4. Infarct size and recovery of left ventricular developed
pressure (LVDP) when drugs were administered at 10 µM
concentration. Top panel: Infarct size, measured as percent of left
ventricular mass (% LV). Bottom panel: LVDP at the end of
reperfusion, expressed as percent of basal values before ischemia
(% BC). *p<0.05; **p < 0.01 vs. control.
Fig. 5. Infarct size and recovery
of left ventricular developed
pressure (LVDP) at the end of
reperfusion when HYB was
administered during mKATP
channel blockade by 5-HD.
Infarct size was measured as a
percent of the left ventricle mass
(% LV); recovery of LVDP is
expressed as percent of basal
values before ischemia (% BC).
Panel A: Infarct size (top) and
LVDP (bottom) when HYB was
administered at 1 µM, with and
without 5-HD. Panel B: Infarct
size (top) and LVDP (bottom)
when HYB was administered at
10 µM, with and without 5-HD.
*p<0.05, **p < 0.01 vs. control;
#p<0.05, ##p<0.01 vs. HYB.
Effects with mKATP channel blockade
After blockade of mKATP channels by 5-HD, the effects of
HYB on infarct size were reversed. When HYB was given at 1 µM
concentration, protection was lost: in comparison with controls,
infarct size was not significantly reduced (49±4% and 54±3%;
p=NS) (Fig. 5A, top panel), and no significant recovery of LVDP
was observed (Fig. 5A, bottom panel).
In sharp contrast, when HYB was given at 10 µM
concentration, a significant reduction of infarct size from 54±3%
to 32±2% was obtained (p<0.01) (Fig. 5B, top panel),
accompanied by a significant recovery of LVDP (51±6%;
p<0.05) (Fig. 5B, bottom panel).
DISCUSSION
The present study demonstrates that the protection involves
both a better recovery of post-ischemic systolic function
(improved LVDP) and a reduction of infarct size when hearts are
treated with the novel HYB at 1 µM. A similar protective effect
is observed with higher concentration (10 µM) of either AOX or
MIX. On the other hand at 1 µM concentration either NOD or
MIX can improve the LVDP recovery without causing a
significant reduction of the infarct size. While NOD and HYB
were ineffective at 10 µM concentration, AOX alone was
ineffective at 1 µM concentration. Thus, with the exception of
HYB, the treatments are either partially protective (better
recovery of systolic function only) when contain low NOD
concentration or fully protective (infarct size reduction and
recovery of LVDP) when include a high AOX concentration.
The novelty of the present study consists in the synergy between
the NO-donor and antioxidant effects in 1 µM HYB. This
synergy seems to consist mainly in the enhancement of the
partially beneficial effect of a low concentration of NOD by the
contribution of antioxidant at an otherwise ineffective
concentration. It is likely that at 1 µM both leads of HYB reach
the appropriate intracellular concentration to achieve both
limitation of infarct size and improvement of contractile
recovery. In fact HYB molecule may allow the NO-donor
portion to enter the cell easily, thus enhancing is availability in
the right moment in the right intracellular site.
It seems surprising that HYB at a higher concentration (10 µM)
induced neither reduction of infarct size nor significant recovery of
LVDP. The different results obtained at 1 and 10 µM of HYB may
be explained by the different effects of low and high NO
concentration on ROS release and myocardial contractility. The
protective role of low levels of ROS has been confirmed in a
number of studies (13, 19, 25, 26). In particular, in the survival
pathway of myocardial protection, ROS have been shown to be
produced in response to opening of mKATP channels elicited by a
signaling cascade triggered by NO (21). Since we gave different
amounts of HYB with different NO release capacities, we suggest
that the protective role of NO-triggered ROS release is likely to be
related to the limited quantity and the proper timing of their release,
as it occurred when the compounds containing NOD were given at
1 µM concentration. It is also possible that, if the amount of NO-
triggered ROS release exceeds a certain, though unknown, value,
their damaging effect counteracts the protective role, as it may have
occurred when NOD or HYB was administered at 10 µM
concentration. This is in keeping with the previous studies
reporting that both a burst of ROS and an impaired availability of
NO contribute to I/R injury (9, 27). This is also in line with the
observation that diazoxide given after ischemia induces a ROS
burst which can (15) or cannot (4, 15) be protective, depending on
modality of administration. As regards the contractile recovery, it
has been reported that, while low concentrations of NO induce a
positive inotropic effect, high concentrations cause a loss of
contractility (18, 28). The former effect is mainly attributed to
prevalence of the cGMP-induced inhibition of phosphodiesterase
III and accumulation of cAMP (28), the latter to prevalence of the
effect of PKG activation and ROS formation (18, 28, 29). This
explanation seems to be corroborated by ongoing experiments with
different hybrid compounds, bearing the same antioxidant moiety
but with a stronger NO-donor substructures. The results suggest
that an excess availability of NO prevents myocardial protection
(unpublished observations).
Data obtained with MIX are also in line with this explanation.
In fact, unlike HYB, MIX is protective at 10 µM concentrations.
At this concentration, the effect of the high concentration of AOX
seems to prevail over the detrimental effect of the high
concentration of NOD. The two different effects of HYB and MIX
at 10 µM concentrations may also be attributed to the different
liposolubility of NOD and AOX present in the MIX, which could
result in greater concentration of AOX in comparison with NOD
inside the cell. On the other hand, as said above, since HYB
contains both pharmacophors in the same molecule, it brings the
NO-donor portion inside the cell easily, and therefore the high
intracellular NO concentration limits protection.
In the present investigation, the dual effect of NO is in
keeping with the behavior of NOD alone: 10 µM concentrations
of this compound did not show any effect on infarct size and
LVDP recovery (Fig. 4), while at lower concentrations (1 µM) a
trend towards a protective effect was observed, as evidenced by
the significant recovery of LVDP only (Fig. 3).
NO-donors may differently influence the activity of
antioxidant enzymes, depending on the protocol of treatment and
the studied tissues. For instance, various NO-donors have been
seen to increase superoxide dismutase (SOD) activity in gastric
tissue and to protect it against the injury by water immersion
restraint (30). In myocardium of spontaneously hypertensive rats
(SHR) NO-donor pentaerythrityl tetranitrate (PETN) improved
SOD activity and reduced cardiac hypertrophy (31, 32).
However, Kristek et al. concluded that PETN "does not result in
a beneficial effect on the myocardium and on the geometry of
carotid and coronary arteries" (31).
It may then be argued that, to protect the heart also against
infarct size, the beneficial NOD effect should be integrated by an
exogenous antioxidant activity as it occurs with 1 µM HYB. In
addition to the availability of NO, the protection offered by HYB
is likely to be due to intracellular scavenging of excessive ROS
with prevention of membrane lipid peroxidation (33).
The involvement of ROS in the different effect of low and
high concentrations of NO released by HYB has been also
suggested by the experiments in which mKATP channels were
blocked and NO cascade was prevented from inducing ROS
production by mitochondria. In these experiments, when HYB
was given at 1 µM concentration, infarct size was not reduced
because the protective NO cascade was interrupted by mKATP
blockade in the presence of an otherwise ineffective antioxidant
concentration. Conversely, at the concentration of 10 µM, the
dangerous effect of the high concentration of NO was prevented
by mKATP blockade, so that the strong antioxidant activity of the
compound at this concentration was not impaired. These results
bring further support to the hypothesis that NO effect is mediated
by mKATP channels, which can limit or increase infarct size via
the production of low or high ROS levels, respectively (21, 22).
Our conclusions about the role of NO-ROS pathway in
myocardial protection are based on the previous demonstration,
by our and other groups, that in isolated hearts and
cardiomyocytes protection induced by NO occurs via ROS
release from mitochondria after opening of mKATP channels
both in pre- and post-conditioning (4, 13, 15, 21). Nevertheless,
ROS may exert divergent effects, depending on the site, time,
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and amount of their generation; they are thus double-edged
sword and our data with mKATP channel blocker suggest a
pivotal role for NO-triggered ROS release in both protection and
reperfusion injury, depending on the amount of available NO-
donor. This hypothesis deserves future studies to be
demonstrated.
After ischemia a clear pulsatile activity was observed in only
4 out of 7 experiments of the control group, while it reappeared
in most of the protected hearts (1 µM of HYB, 10 µM of AOX
and 10 µM of MIX); this different recovery might also be
considered an additional marker of protection.
Compared with the other effective treatments, the effect of
HYB at 1 µM concentration is important not only because of the
significant reduction of infarct size, recovery of LVDP and
increased rate of reappearance of pulsatile activity, but also because
of the small dose required to produce all features of protection. In
addition, the effect of HYB was obtained with one molecule only
that allows the same pharmacokinetics for the two leads.
Overall, our data support the idea that the timing and
intracellular compartmentalization of NO release and ROS
scavenging are important issues. These might explain the lack of
effects of antioxidant therapies only and the seemingly
deleterious effect of antioxidant pretreatment in clinical setting
(9, 10). Yet, since HYB is effective if given at low concentration
at the time of reperfusion, it might represent a promising clinical
tool, because it could be administered to patients after the onset
of infarction, at the time of reperfusion.
CONCLUSION
In conclusion, administration of an hybrid compound with
both NO-donor and antioxidant properties may represent a novel
therapeutic strategy against ischemia-reperfusion injury if
infused in the coronary stream at the beginning of reperfusion,
and at a dose which causes the appropriate balance between NO
donor and antioxidant activity. Our experiments suggest that the
antioxidant moiety may help the cell permeation and the activity
of the low concentration of NO released by the HYB at 1 µM
concentration. Finally, our data suggest that the protective
effects of 1 µM of HYB are mediated at least in part by mKATP
channel activation.
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